Inhibition of DNA methyltransferase activates tumor necrosis factor α-induced monocytic differentiation in acute myeloid leukemia cells

Cancer Research

Volumn 69, Issue 1, 2009, Pages 55-64

  Laurenzana, Anna ^a,b   Petruccelli, Luca A ^a,b   Pettersson, Filippa ^a,b   Figueroa, Maria Eugenia ^c   Melnick, Ari ^c   Baldwin, Albert S ^d   Paoletti, Francesco ^e   Miller Jr , Wilson H ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RNA POLYMERASE II; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN U937; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; CONTROLLED STUDY; DEACETYLATION; DIF 2 GENE; DNA METHYLATION; DRUG POTENCY; ENZYME INHIBITION; EPIGENETICS; GENE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LEUKEMIA CELL LINE; LEUKEMOGENESIS; LOW DRUG DOSE; MONOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ACETYLATION; ACUTE DISEASE; AZACITIDINE; CELL DIFFERENTIATION; CHROMATIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; HISTONES; HUMANS; LEUKEMIA, MYELOID; MONOCYTES; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; PROMOTER REGIONS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 58249110388     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0245     Document Type: Article

References (49)

1. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
2. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999;99:451-4.
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
4. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 1982;257:2041-8.
5. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58:95-101.
6. Momparler R, Bouchard J, Samson J. Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine. Leuk Res 1985;9:1361-6.
7. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-86.
8. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 1999;18:6910-24.
9. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-7.
10. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
11. Chen F, Castranova V. Nuclear factor-κB, an unappreciated tumor suppressor. Cancer Res 2007;67:11093-8.
12. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503.
13. Kisseleva T, Song L, Vorontchikhina M, Feirt N, Kitajewski J, Schindler C. NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancer. J Clin Invest 2006;116:2955-63.
14. Witcher M, Shiu HY, Guo Q, Miller WH, Jr. Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. Blood 2004;104:3335-42.
15. Laurenzana A, Pettersson F, Miller WJ. Role of PML/RARα in the pathogenesis of APL. Drug Discovery Today Disease Mechanisms 2006;3:499-505.
16. Licht JD. Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell 2006;9:73-4.
17. Witcher M, Ross DT, Rousseau C, Deluca L, Miller WH, Jr. Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. Blood 2003;102:237-45.
18. Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller WH, Jr. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996;88:2671-82.
19. Witcher M, Pettersson F, Dupere-Richer D, et al. Retinoic acid modulates chromatin to potentiate tumor necrosis factor α signaling on the DIF2 promoter. Nucl Acids Res 2008;36:435-43.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidiniumthiocyanatephenol-chloroformex traction. Anal Biochem 1987;162:156-9.
21. Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-κB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001;166:7128-35.
22. Hass R, Bartels H, Topley N, et al. TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens. Eur J Cell Biol 1989;48:282-93.
23. Ferreira OC, Jr., Valinsky JE, Sheridan K, Wayner EA, Bianco C, Garcia-Pardo A. Phorbol ester-induced differentiation of U937 cells enhances attachment to fibronectin and distinctly modulates the α5β1 and α4β1 fibronectin receptors. Exp Cell Res 1991;193:20-6.
24. Charrad RS, Gadhoum Z, Qi J, et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002;99:290-9.
25. Clark CS, Konyer JE, Meckling KA. 1α,25-Dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression. Exp Cell Res 2004;294:301-11.
26. Lu R, Pitha PM. Monocyte differentiation to macrophage requires interferon regulatory factor 7. J Biol Chem200 1;276:45491-6.
27. Sykes DB, Scheele J, Pasillas M, Kamps MP. Transcriptional profiling during the early differentiation of granulocyte and monocyte progenitors controlled by conditional versions of the E2a-Pbx1 oncoprotein. Leuk Lymphoma 2003;44:1187-99.
28. Sherman ML, Stone RM, Datta R, Bernstein SH, Kufe DW. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem 1990;265:3320-3.
29. Pietzsch A, Buchler C, Schmitz G. Genomic organization, promoter cloning, and chromosomal localization of the Dif-2 gene. Biochem Biophys Res Commun 1998;245:651-7.
30. Ziegelbauer K, Gantner F, Lukacs NW, et al. A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 2005;145:178-92.
31. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 1984;81:6993-7.
32. Bestor TH. Gene silencing. Methylation meets acetylation. Nature 1998;393:311-2.
33. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000;14:2314-29.
34. Hirose Y, Ohkuma Y. Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem Tokyo 2007;141:601-8.
35. Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Current cancer drug targets 2008;8:124-31.
36. Kuwano K, Hara N. Signal transduction pathways of apoptosis and inflammation induced by the tumor necrosis factor receptor family. Am J Respir Cell Mol Biol 2000;22:147-9.
37. Pietzsch A, Buchler C, Aslanidis C, Schmitz G. Identification and characterization of a novel monocyte/macrophage differentiation-dependent gene that is responsive to lipopolysaccharide, ceramide, and lysophosphatidylcholine. Biochem Biophys Res Commun 1997;235:4-9.
38. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science 1998;281:998-1001.
39. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
40. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91.
41. Robert MF, Morin S, Beaulieu N, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33:61-5.
42. Santi DV, Garrett CE, Barr PJ. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 1983;33:9-10.
43. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-9.
44. Koturbash I, Boyko A, Rodriguez-Juarez R, et al. Role of epigenetic effectors in maintenance of the long-term persistent bystander effect in spleen in vivo. Carcinogenesis 2007;28:1831-8.
45. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′- deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985;30:277-86.
46. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006;12:5777-85.
47. Weiser TS, Guo ZS, Ohnmacht GA, et al. Sequential 5-aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 2001;24:151-61.
48. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-α in cancer patients. J Clin Oncol 1988;6:1328-34.
49. Witcher M, Pettersson F, Dupere-Richer D, et al. Retinoic acid modulates chromatin to potentiate tumor necrosis factor a signaling on the DIF2 promoter. Nucleic Acids Res 2008;36:435-43.